Navigation Links
Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
Date:7/21/2009

PRINCETON, N.J. and SAN DIEGO, July 22 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two Phase I pharmacokinetic studies for TAK-652, an investigational compound being developed for the treatment of HIV. These data suggest that TAK-652 is rapidly absorbed and demonstrate relatively good oral bioavailability (as shown by the plasma TBR-652 concentration data) and has a long plasma half-life of TBR-652 (approximate mean of 35 hours) supporting once-daily dosing. Mean TBR-652 plasma concentrations were well above the predicted target plasma concentration (2ng/mL) with or without food. In both studies TBR-652 was safe and well tolerated in this healthy subject population when administered over a dose range of 10 mg to 800 mg in 2 tablet formulations. "These two Phase I studies provide encouraging support for TAK-652 as a therapeutic option for the treatment of HIV. We look forward to results from our on-going proof-of-concept study," said James Sapirstein, CEO.

These data were presented at the 5th International Conference on HIV Pathogenesis, Treatment and Prevention, held July 19-23, 2009 in Cape Town, South Africa. Both poster presentations can be viewed at www.tobiratherapeutics.com.

About Tobira Therapeutics Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced managem
'/>"/>

SOURCE Tobira Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Tobira Therapeutics Inc. Announces Senior Management Team
2. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
3. Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  Replikins Ltd. today released new data on changes ... the current outbreaks, the mean Ebola Reston gene Replikin ... 1995 and 2002 was 1.1; the mean Replikin Count ... in 2013, thus predicting the current outbreaks in humans. ... shown to be able to predict outbreaks (1).  For ...
(Date:7/30/2014)... 2014 With the accelerated aging ... health expenditure as well as the improved medical ... diagnostic reagent industry has been developing quickly, especially ... 2013, Chinese in vitro diagnostics market size reached ... in vitro diagnostic reagents. , Read complete ...
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
(Date:7/30/2014)... MARLBOROUGH, Mass. , July 30, 2014 ... RXII ), a biotechnology company focused on ... major unmet medical needs using RNA-targeted technologies, ... study (RXI-109-1402) with RXI-109, for the reduction ... scar revision surgery, has been initiated. ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... technology professionals often face the challenge of delivering ... maximize both storage and bandwidth efficiency, while providing ... announced SecureZip, a new family of products designed ... in a cross-platform environment. The company also introduced ...
... Sanyo have announced they will work together to produce ... ,Sanyo will be working with Rayovac's I-C3 technology, which the ... in 15 minutes. I-C3, or In-Cell Charge Control, is a ... regulates the charging mechanism, rather than allowing the charger free ...
... when entrepreneur Ken Schlager started a company, he looked ... This time around, Schlager is turning to the Center ... he launches a cutting-edge technology that applies electromagnetic fields ... has developed a process that oxidizes wastewater and removes ...
Cached Biology Technology:PKWare launches new enterprise product line, adds new features to PKZip 2PKWare launches new enterprise product line, adds new features to PKZip 3CTT - Bridging the states entrepreneurial gap 2CTT - Bridging the states entrepreneurial gap 3
(Date:7/30/2014)... Americans make better decisions about what they eat, the ... significant changes to the Nutrition Facts label found on ... in Chemical & Engineering News (C&EN), the ... the suggested updates and the fight that has ... points out that while the Nutrition Facts label has ...
(Date:7/30/2014)... awarded the Scientific Committee on Antarctic Research,s (SCAR) ... SCAR, an inter-disciplinary international science body, initiates, develops ... the Antarctic region, and on the role of ... organisation also provides scientific advice about Antarctica to ... region. , The medal is open internationally to ...
(Date:7/30/2014)... a multitude of cells types. Researchers would like to understand ... mature cells that make up the organs and other structures ... long chains of sugars that dangle from proteins on surfaces ... California, San Diego, has created synthetic molecules that can stand ... manipulated to direct the process, they report in the ...
Breaking Biology News(10 mins):
... is a well-known cause of cardiovascular disease, research from the ... revealed that the body,s obesity hormones adiponectin - are ... Our skeleton is more than just bones, vertebrae ... is constantly linked to our brain, our muscles and our ...
... LANSING, Mich. Discovering new treatments and battling dangerous ... researchers targeting the genetic disorder cystic fibrosis with projects ... research studies, with support from a $110,000 grant from ... and Translational Sciences Institute, expand the relationship between the ...
... 1st, 2011) Policy decisions and poor management have ... national security, according to an article available today in ... Scientists, published by SAGE. The article calls into question ... scientists for the decline. , According to George Mason ...
Cached Biology News:4 projects target cystic fibrosis with Hunt for a Cure funds 2Structure, not scientists to blame for Los Alamos failings 2Structure, not scientists to blame for Los Alamos failings 3
... Development kit contains the basic components required ... measure natural and recombinant rat L-Selectin in ... kit contains sufficient materials to run ELISAs ... the following conditions are met: ...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
Recombinant Ovine (Sheep) Growth Hormone, Ultra Pure...
Request Info...
Biology Products: